Abstract
Lung cancer is the most common cause of cancer-related death worldwide, owing to its metastatic spread at the time of diagnosis. As a result, chemotherapy is the standard of care for the majority of patients. In recent years, the role of chemotherapy has expanded to include maintenance therapy and approved second-and third-line treatments. Nonetheless, traditional chemotherapy has modestly improved outcomes in patients with advanced non-small-cell lung cancer (NSCLC). Research efforts have been redirected toward the integration of molecularly-targeted agents into a treatment algorithm with unprecedented survival rates in selected patients. This article will provide an update on the multiple systemic regimens available to treat NSCLC, and discuss emerging molecular-based therapies.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 629-639 |
| Number of pages | 11 |
| Journal | Clinical Advances in Hematology and Oncology |
| Volume | 11 |
| Issue number | 10 |
| State | Published - Oct 2013 |
Fingerprint
Keywords
- Chemotherapy
- Maintenance therapy
- Molecularly targeted therapy
- Non-small-cell lung cancer
ASJC Scopus subject areas
- Oncology
- Hematology
Cite this
Treatment paradigms in advanced non-small-cell lung cancer. / Mccoach, Caroline E.; Kelly, Karen.
In: Clinical Advances in Hematology and Oncology, Vol. 11, No. 10, 10.2013, p. 629-639.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Treatment paradigms in advanced non-small-cell lung cancer
AU - Mccoach, Caroline E.
AU - Kelly, Karen
PY - 2013/10
Y1 - 2013/10
N2 - Lung cancer is the most common cause of cancer-related death worldwide, owing to its metastatic spread at the time of diagnosis. As a result, chemotherapy is the standard of care for the majority of patients. In recent years, the role of chemotherapy has expanded to include maintenance therapy and approved second-and third-line treatments. Nonetheless, traditional chemotherapy has modestly improved outcomes in patients with advanced non-small-cell lung cancer (NSCLC). Research efforts have been redirected toward the integration of molecularly-targeted agents into a treatment algorithm with unprecedented survival rates in selected patients. This article will provide an update on the multiple systemic regimens available to treat NSCLC, and discuss emerging molecular-based therapies.
AB - Lung cancer is the most common cause of cancer-related death worldwide, owing to its metastatic spread at the time of diagnosis. As a result, chemotherapy is the standard of care for the majority of patients. In recent years, the role of chemotherapy has expanded to include maintenance therapy and approved second-and third-line treatments. Nonetheless, traditional chemotherapy has modestly improved outcomes in patients with advanced non-small-cell lung cancer (NSCLC). Research efforts have been redirected toward the integration of molecularly-targeted agents into a treatment algorithm with unprecedented survival rates in selected patients. This article will provide an update on the multiple systemic regimens available to treat NSCLC, and discuss emerging molecular-based therapies.
KW - Chemotherapy
KW - Maintenance therapy
KW - Molecularly targeted therapy
KW - Non-small-cell lung cancer
UR - http://www.scopus.com/inward/record.url?scp=84887101376&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84887101376&partnerID=8YFLogxK
M3 - Article
C2 - 24518373
AN - SCOPUS:84887101376
VL - 11
SP - 629
EP - 639
JO - Clinical Advances in Hematology and Oncology
JF - Clinical Advances in Hematology and Oncology
SN - 1543-0790
IS - 10
ER -